Kato, Japan

Kazuki Taguchi

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Agc Inc., Nippon Zoki Pharmaceutical Co., Ltd.. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuki Taguchi: Innovator in Prostaglandin Derivatives

Introduction

Kazuki Taguchi is a notable inventor based in Kato, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on prostaglandin derivatives. His research has led to advancements that may benefit various medical applications.

Latest Patents

Kazuki Taguchi holds a patent for a novel prostaglandin derivative. This invention features an alkynyl group on the ω-chain and includes a double bond at the 2-position. The compound is represented by a specific formula and is intended for use as an active ingredient in medicaments. He has 1 patent to his name, showcasing his expertise in this specialized area.

Career Highlights

Throughout his career, Taguchi has worked with prominent companies such as AGC Inc. and Nippon Zoki Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical industry.

Collaborations

Kazuki Taguchi has collaborated with esteemed colleagues, including Arata Yasuda and Yasushi Matsumura. These partnerships have likely contributed to the success of his projects and the advancement of his research.

Conclusion

Kazuki Taguchi's work in developing prostaglandin derivatives highlights his innovative spirit and dedication to improving medical treatments. His contributions to the field are noteworthy and reflect his commitment to advancing pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…